| Document |
Document Title |
|
WO/2017/161144A1 |
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The prese...
|
|
WO/2017/161356A1 |
Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeuti...
|
|
WO/2017/156630A1 |
The present description relates to a conjugated compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear localization sequence (NLS) conjugated to a compound ...
|
|
WO/2017/161170A1 |
The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the u...
|
|
WO/2017/152821A1 |
Disclosed are an isoquinoline compound, and intermediates, a preparation method and an application thereof. The isoquinoline compound of the present invention has a structure as represented by formula I, wherein R1 and R2 are each indepe...
|
|
WO/2017/155926A1 |
Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates ...
|
|
WO/2017/153345A1 |
The present disclosure relates to radiolabeled binding agents (e.g. antibodies, such as, without limitation, single-domain antibodies) which bind CD20 and their use as diagnostic, prognostic, predictive and therapeutic agents.
|
|
WO/2017/155937A1 |
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on variou...
|
|
WO/2017/150549A1 |
The present invention pertains to a compound, etc., from which is obtained a radiolabeled drug capable of reducing accumulation in the kidneys from early administration. [1] A compound, etc., represented by formula (1); [2] a compound, e...
|
|
WO/2017/152127A1 |
A composite implant (100) for providing simultaneous magnetic resonance imaging (MRI) and computed tomographic (CT) imaging contrast is disclosed. The composite implant (100) is formed of a calcium compound (120) in the form of nano or m...
|
|
WO/2017/148925A1 |
The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo dia...
|
|
WO/2017/147159A1 |
The present invention provides compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
|
|
WO/2017/144959A1 |
An apparatus is described for labelling molecules with gallium-68, for eluting all gallium-68 generators presently available on the market, by means of a single, single-use labelling circuit (CM) for purifying radioactive material, in or...
|
|
WO/2017/138983A1 |
Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer -EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therap...
|
|
WO/2017/136326A1 |
The present invention includes a method of measuring thyroid function comprising identifying a subject in need of measuring thyroid function or structure; providing the subject with an amount of an organified iodine sufficient to cause t...
|
|
WO/2017/134098A1 |
The present invention relates to novel, selective radiolabelled tau ligands which are useful for imaging and quantifying tau aggregates, using positron-emission tomography (PET). The invention is also directed to compositions comprising ...
|
|
WO/2017/127357A1 |
A DNA aptamer is provided that binds to a cholecystokinin B receptor (CCBKR), allowing for delivery of therapeutic agents or imaging agents to cells having the CCBKR. Compositions and methods of use are provided where the aptamer binds t...
|
|
WO/2017/126939A1 |
The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by projecting an electron beam to an aqueous solution comprising at least one substance select...
|
|
WO/2017/121858A1 |
The invention relates to a novel use of ultrafine nanoparticles as an imaging agent in a method for diagnosing a renal disorder. The invention also relates to the use of ultrafine nanoparticles as an imaging agent in methods for monitori...
|
|
WO/2017/122205A1 |
Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distributi...
|
|
WO/2017/121436A1 |
There is provided a positron-emitting 18F-labelled Factor VIIfor non-invasive PET imaging of tumor TF expression in humans. More specifically the invention relates to human TFPET imaging of pancreaticcancer metastasis for diagnosis, stag...
|
|
WO/2017/117687A1 |
This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each Rl is an an...
|
|
WO/2017/118593A1 |
The invention provides a method for the purification of 227 Th from a mixture comprising 227 Th and 223 Ra, said method comprising: i) preparing a first solution comprising a mixture of 227 Th and 223 Ra ions dissolved in a first aqueous...
|
|
WO/2017/118591A1 |
The present invention comprises a method for the generation of 227 Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227 Ac, 227 Th and 223 Ra; ii) loading said generator mixture onto a strong...
|
|
WO/2017/118596A1 |
The invention provides a method for the purification of complexed 227Th from a mixture comprising complexed 227Th and 223Ra (complexed or in solution), said method comprising: i) preparing a first solution comprising a mixture of complex...
|
|
WO/2017/118592A1 |
The present invention provides a method for the purification of 227Th from a mixture comprising 227Th and 223Ra, said method comprising: i) preparing a first solution comprising a mixture of 227Th and 223Ra ions dissolved in an aqueous s...
|
|
WO/2017/114317A1 |
Disclosed is a compound capable of specifically binding with β amyloid protein. The compound has thereon a nuclide having a large cross section for capturing thermal neutrons and the compound is capable of specifically binding with β a...
|
|
WO/2017/117196A1 |
Described herein are methods for the treatment of heavily pre-treated recurrent ovarian cancer. In particular, methods are provided for the treatment of heavily pre-treated recurrent ovarian cancer with a combination of entinostat and an...
|
|
WO/2017/117274A1 |
Disclosed herein, inter alia, are methods for detecting cancer using nanoparticles.
|
|
WO/2017/117199A1 |
The present invention is directed to novel non-invasive diagnostic took to dispose numerous disease states and/or conditions. The presets invention, represents a clear advance in the art which presently relies on tissue biopsy for diagno...
|
|
WO/2017/115943A1 |
The present invention relates to a biopatch and a preparation method therefor and, more specifically, to a biopatch and a preparation method, the biopatch having metal nanoparticles, on which a biofunctional material layer and an organic...
|
|
WO/2017/111220A1 |
The present invention relates to a method for producing a [11C] radiopharmaceutical product and, particularly, discloses a method for producing a radiopharmaceutical product, the method comprising a step for performing the [11C] methylat...
|
|
WO/2017/111403A2 |
The present inventions relates to a method for producing a radioactive compound containing [18F] and, particularly, discloses discloses a method for producing a radioactive compound containing [18F], the method comprising: i) a step for ...
|
|
WO/2017/110746A1 |
The purpose is to provide gelatin particles easily taken up by cells themselves that are gelatin particles crosslinked without using a crosslinking agent, and a method for producing such gelatin particles. The invention pertains to gelat...
|
|
WO/2017/111402A1 |
The present invention relates to a radioactive compound to which [18F]alkyl is introduced as a tracer for PET for diagnosing brain neural inflammation, and to a method for producing said radioactive compound.
|
|
WO/2017/106340A1 |
Methods of C-H bond fluorination using non-heme manganese catalyst are described herein. For example, a method comprises providing a reaction mixture including a non-heme manganese catalyst, a substrate comprising an sp3 C-H bond and a f...
|
|
WO/2017/103190A1 |
The present invention relates to cyclic preS-derived peptides of HBV which are versatile vehicles for the targeted delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention further ...
|
|
WO/2017/103179A1 |
The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission...
|
|
WO/2017/102906A1 |
The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The ...
|
|
WO/2017/106253A1 |
Conformationally strained irans-cycloalkenes and derivatives thereof suitable for radiolabeling in a subject in need thereof.
|
|
WO/2017/105565A2 |
Described herein is a chelator for radiolabels (e.g., 89Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for 89Zr is the ligand, 3,4,3-(LI-1,2- HOPO) ("HOPO"), which exhibits equal or super...
|
|
WO/2017/106525A1 |
Described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate specific nerves (e.g., sensory nerves vs. motor nerves) for nerve transplants and other surgeries. Also d...
|
|
WO/2017/101717A1 |
Provided are a mitochondrial targeting contrast agent molecule and use thereof as a T 2 contrast agent. The mitochondrial targeting contrast agent molecule comprises a phosphonium cation of formula -P +(X 1)(X 2)(X 3) for binding to cell...
|
|
WO/2017/103257A1 |
The present invention provides methods useful in the management neuropathological conditions where expression of monoamine oxidase B (MAO-B) deviates from that seen in healthy subjects. The invention provides for the use of compounds in ...
|
|
WO/2017/103182A1 |
The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emi...
|
|
WO/2017/095806A1 |
New methodologies for site-specifically radiolabeling proteins with the PET isotope [18F] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overc...
|
|
WO/2017/091905A1 |
There is provided a single variable domain T-cell receptor (svd-TCR) comprising a first TCR variable domain, the first TCR variable domain specifically binding to an epitope, that is not a superantigen, in the absence of a second TCR var...
|
|
WO/2017/078761A9 |
Disclosed are highly potent peptides, peptide conjugates, host cells and compositions containing one or more of these peptides, peptide conjugates and/or host cells that are useful to inhibit the growth of a breast cancer cell or treat b...
|
|
WO/2017/096124A1 |
A fusion protein, comprising: (i) a first vascular endothelial growth factor (VEGF) isoform, and (ii) a second VEGF isoform, and (iii) a dimerization domain between the first isoform and the second isoform, wherein the first isoform and ...
|
|
WO/2017/089847A1 |
The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(II), Fe(II), Fe(III), Co(II) and Ni(II) complexes. The other subject of the invention is the applic...
|
